Cargando…

The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies

Multiple myeloma (MM) is a heterogeneous plasma cell disorder characterized by genetic abnormalities, including chromosomal translocations, deletions, duplications and genetic mutations. Translocations involving the immunoglobulin heavy chain region at chromosome 14q32 are observed in approximately...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalff, A, Spencer, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461707/ https://www.ncbi.nlm.nih.gov/pubmed/22961061 http://dx.doi.org/10.1038/bcj.2012.37

Ejemplares similares

Plasma Membrane Proteomics Identifies Biomarkers Associated with MMSET Overexpression in T(4;14) Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2013)

Epigenomic reprogramming via HRP2-MINA dictates response to proteasome inhibitors in multiple myeloma with t(4;14) translocation
por: Wang, Jingjing, et al.
Publicado: (2022)

The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma
por: Longo, Joseph, et al.
Publicado: (2020)

MMSET is the key molecular target in t(4;14) myeloma
por: Mirabella, F, et al.
Publicado: (2013)

The snoRNA target of t(4;14) in multiple myeloma regulates ribosome biogenesis
por: Oliveira, Vanessa, et al.
Publicado: (2019)

Targeting UCHL1 Induces Cell Cycle Arrest in High-Risk Multiple Myeloma with t(4;14)
por: Kamseng, Parin, et al.
Publicado: (2021)

Super Enhancer-Mediated Upregulation of HJURP Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma
por: Jia, Yunlu, et al.
Publicado: (2022)

Posttranslational modification of Aurora A‐NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma
por: Jiang, Hongmei, et al.
Publicado: (2022)

Concomitant 1q+ and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma
por: Ozga, Michael, et al.
Publicado: (2023)

P807: CLASS Ⅱ FERROPTOSIS INDUCERS ARE A NOVEL THERAPEUTIC APPROACH FOR T(4;14)-POSITIVE MULTIPLE MYELOMA
por: Zhang, Jiasi, et al.
Publicado: (2023)

Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation
por: Diamantidis, Michael D., et al.
Publicado: (2022)

Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions
por: Schavgoulidze, Anaïs, et al.
Publicado: (2023)

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM
por: Stong, Nicholas, et al.
Publicado: (2023)

MB4-2/MB4-3 transcripts of IGH-MMSET fusion gene in t(4;14)(pos) multiple myeloma indicate poor prognosis
por: Li, Feng, et al.
Publicado: (2017)

Implementation of KK for DELPHI (DElKK version 4.14/6)
por: Andringa, S, et al.
Publicado: (2003)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
por: Nguyen, Nina, et al.
Publicado: (2022)

Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
por: Ceglédi, Andrea, et al.
Publicado: (2023)

Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients
por: Calura, Enrica, et al.
Publicado: (2015)

Scientific opinion on flavouring group evaluation 414 (FGE.414): 2‐hydroxy‐4‐methoxybenzaldehyde
por: Younes, Maged, et al.
Publicado: (2021)

The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice
por: Turner, Rose, et al.
Publicado: (2022)

Inactivation of BANK1 in a novel IGH-associated translocation t(4;14)(q24;q32) suggests a tumor suppressor role in B-cell lymphoma
por: Yan, J, et al.
Publicado: (2014)

Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society
por: Abe, Yoshiaki, et al.
Publicado: (2019)

Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2022)

A Novel Function of Sphingosine Kinase 2 in the Metabolism of Sphinga-4,14-Diene Lipids
por: Couttas, Timothy Andrew, et al.
Publicado: (2020)

Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
por: Cardona-Benavides, Ignacio J., et al.
Publicado: (2021)

Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma
por: Ruiz-Heredia, Yanira, et al.
Publicado: (2021)

Pathological and Prognostic Impacts of FGFR2 Overexpression in Gastric Cancer: A Meta-Analysis
por: Kim, Hyeong Su, et al.
Publicado: (2019)

414 Housing and Environmental Exposures: A Systematic Literature Review on Research and Policy Implications
por: Bhat, Aarti C., et al.
Publicado: (2023)

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
por: Barwick, Benjamin G., et al.
Publicado: (2019)

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)
por: Kalff, Anna, et al.
Publicado: (2021)

Pleural effusion in 11:14 translocation q1 multiple myeloma in the setting of proteasome inhibitor presents therapeutic complexity
por: Ghannam, Malik, et al.
Publicado: (2018)

Near tetrapoloid karyotype with translocation t(11;14) in a Moroccan patient with amyloid light-chain amyloidosis and multiple myeloma
por: Hamdaoui, Hasna, et al.
Publicado: (2020)

Memorandum: status of analysis of experiment R414
por: CERN. Geneva. Intersecting Storage-Rings Committee
Publicado: (1978)

FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro
por: Künstlinger, Helen, et al.
Publicado: (2015)

Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma
por: Painuly, Utkarsh, et al.
Publicado: (2018)

Prognostic implications of Fibroblast growth factor receptor 1 (FGFR1) gene amplification and protein overexpression in hypopharyngeal and laryngeal squamous cell carcinoma
por: Kim, Eun Kyung, et al.
Publicado: (2020)

(414) Low Incidence of Long COVID in Heart Transplant Recipients
por: Feinman, J., et al.
Publicado: (2023)

1-Hydroxymethyl-3,12-dioxa-14-azatetracyclo[9.2.1.0(4,14).0(5,10)]tetradecane
por: Tai, Xi-Shi, et al.
Publicado: (2008)

Prognostic implications of FGFR1 and MYC status in esophageal squamous cell carcinoma
por: Kwon, Dohee, et al.
Publicado: (2016)

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
por: Nijhof, Inger S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7gdojfg7u403k9tdfqncsr200b